BCM-95® (CURCUGREEN®), 23 Mar 2013
Published on : J Complement Integr Med . 2013 Jul 1;10:/j/jcim.2013.10.issue-1/jcim-2012-0011/jcim-2012-0011.xml. doi: 10.1515/jcim-2012-0011.
Jennifer J Moreillon 1, Rodney G Bowden, Erika Deike, Jackson Griggs, Ron Wilson, Brian Shelmadine, Matt Cooke, Alexander Beaujean
PMID: 23828329 DOI: 10.1515/jcim-2012-0011
Doi 10.1515/jcim-2012-0011 J Complement Integr Med. 2013; 10(1): 143–152
Scientists: Jennifer J. Moreillon, Rodney G. Bowden*, Erika Deike, Jackson Griggs, Ron Wilson, Brian Shelmadine, Matt Cooke and Alexander Beaujean
Abstract: A study that demonstrates that mild and moderate Chronic kidney disease (CKD) is associated with chronic inflammation and low antioxidant activity. Systemic inflammation and impaired antioxidant status may be greater in CKD populations with multiple comorbidities. Curcumin and Boswellia serrata are safe and tolerable and helped to improve the levels of an inflammatory cytokine.
Methods: Participants were randomly chosen to receive a herbal supplement composed of a combination of curcumin and Boswellia serrata (824 mg purified turmeric extract, 95% curcuminoids, and 516 mg Boswellia serrata extract, 10% 3-acetyl-11-keto-β-boswellic acid) or placebo (roasted rice powder). The participants continued to follow the treatment protocols by their treating physician. The study supplement was an additional treatment beyond the patients’ standard care.
Results: Baseline values of C-reactive protein (CRP) were significantly lower in the treatment group compared to the placebo group. Post-study levels of CRP were also significantly lower in the treatment group. A significant time effect and time x compliance interaction effect.
Conclusion: CKD is associated with an ongoing inflammatory state and impaired antioxidant activity. This has been the first study to use curcumin and Boswellia serrata in CKD patients. Treatment was well-tolerated and decreased inflammation as measured by IL-6, with no changes observed in any other inflammatory or antioxidant markers. Larger randomized trials are needed to further investigate the role of anti-inflammatory supplements in moderate CKD. Particularly, it is of great importance to determine how these compounds decrease inflammation and thus, cardiovascular mortality.